Septerna (NASDAQ:SEPN) Upgraded to “Hold” at Wall Street Zen

by · The Cerbat Gem

Wall Street Zen upgraded shares of Septerna (NASDAQ:SEPN – Free Report) from a sell rating to a hold rating in a report released on Friday.

SEPN has been the subject of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $26.00 price target on shares of Septerna in a report on Thursday, August 21st. Wells Fargo & Company increased their price target on Septerna from $11.00 to $18.00 and gave the stock an “equal weight” rating in a report on Friday, May 16th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of Septerna in a report on Friday. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Septerna presently has an average rating of “Moderate Buy” and an average target price of $26.75.

Check Out Our Latest Report on SEPN

Septerna Stock Up 2.2%

NASDAQ SEPN opened at $14.43 on Friday. The stock has a fifty day simple moving average of $12.11 and a 200 day simple moving average of $9.14. Septerna has a twelve month low of $4.17 and a twelve month high of $28.99. The company has a market capitalization of $643.29 million and a price-to-earnings ratio of -1.43.

Septerna (NASDAQ:SEPN – Get Free Report) last issued its quarterly earnings results on Monday, August 11th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.51). Septerna had a negative return on equity of 31.52% and a negative net margin of 12,053.03%.The business had revenue of $0.12 million for the quarter, compared to analyst estimates of $22.50 million. Research analysts expect that Septerna will post -7.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Septerna

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Rangeley Capital LLC boosted its position in shares of Septerna by 10.7% during the 2nd quarter. Rangeley Capital LLC now owns 58,605 shares of the company’s stock worth $619,000 after purchasing an additional 5,655 shares in the last quarter. Perceptive Advisors LLC bought a new position in shares of Septerna during the 2nd quarter worth about $5,723,000. Boothbay Fund Management LLC bought a new position in shares of Septerna during the 2nd quarter worth about $255,000. Bank of America Corp DE boosted its position in shares of Septerna by 758.3% during the 2nd quarter. Bank of America Corp DE now owns 99,213 shares of the company’s stock worth $1,049,000 after purchasing an additional 87,654 shares in the last quarter. Finally, VR Adviser LLC bought a new position in shares of Septerna during the 2nd quarter worth about $5,713,000.

About Septerna

(Get Free Report)

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

Read More